drugset
Drugs / YF-17D
last change Nov 2025 re-read 2 minutes ago

YF-17D

also known as YF-VAX

Vaccine

Developed for
Plasmodium falciparum malaria
Investigated by
Defense Advanced Research Projects Agency · Emory University · Leiden University Medical Center · Open Philanthropy · Takeda

Trials 3 · a red edge is where a trial was stopped

today NCT05801978 · Ph 4 NCT05468606 · Ph 0 NCT03342898 · Ph 3
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05468606 Feb 2023 → Dec 2024 Plasmodium falciparum malaria Leiden University Medical Center Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT03342898 Feb → May 2018 dengue disease Takeda Completed No outcome recorded
Phase 41 trial
Phase 4 NCT05801978 Apr 2023 → Sep 2027 expected — Emory University Recruiting No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07527247 Background Nov 2025 → Feb 2029 expected — Singapore General Hospital Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as YF17D “The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial.” NCT05801978 ↗
4

“0.1 mL YF17D vaccine intradermally” NCT05468606 ↗

NCT07527247 ↗

NCT03342898 ↗

NCT05468606 ↗
Known as YF-VAX “The FDA-approved YF-17D (YF-VAX®) is a live attenuated vaccine manufactured by Sanofi Pasteur as a one-dose vial.” NCT05801978 ↗
Modality Vaccine “YF-17D vaccine” NCT03342898 ↗
Route Subcutaneous “YF-17D vaccine, 0.5 mL injection, subcutaneously (SC)” NCT03342898 ↗